logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5115.produseast1
Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries

Zachariah R, Massaquoi M
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Despite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread use might substantially increase bacterial cross-resistance in the community and that this intervention might promote resistance of malaria parasites to sulphadoxine-pyrimethamine. We review the current evidence on the above concerns and highlight the main operational considerations related to implementing CTX prophylaxis as a basic component of care for HIV-positive TB patients in developing countries.

Languages

English
DOI
10.1258/004947506776593314
Published Date
01 Apr 2006
PubMed ID
16611438
Journal
Tropical Doctor
Volume | Issue | Pages
Volume 36, Issue 2
Issue Date
2006-04-01
Dimensions Badge